Scores in Critically Ill Patients After Craniotomy
Launched by BEIJING TIANTAN HOSPITAL · Jan 1, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Scores in Critically Ill Patients After Craniotomy," is studying patients who have had brain surgery (called craniotomy) and were admitted to the intensive care unit (ICU) for at least 24 hours. The researchers at Beijing Tiantan Hospital want to understand how well different scoring systems can predict the outcomes—such as survival rates—of these patients based on their severity of illness. They will collect information from medical records, including patient details, surgery information, and any complications that may arise.
To participate in this trial, patients must be adults who had craniotomy surgery and were admitted to the ICU between 2017 and 2020. However, pregnant or breastfeeding women and those already involved in other clinical studies cannot join. If eligible, participants can expect to have their health data reviewed and to help researchers understand which scoring systems work best for predicting patient outcomes after brain surgery. This information could ultimately help improve care for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the ICU wards between 2017 and 2020
- • Patients underwent craniotomy
- • Patientshad an ICU stay of more than 24 hours
- Exclusion Criteria:
- • Pregnant or lactating women
- • Patients enrolled in other clinical studies
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , Chile
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported